Avicanna (AVCNF) Stock Price, News & Analysis

Company Overview

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific pharmaceutical products to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, such as Trunerox, an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome. It also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, the company operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, and educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens, as well as collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

Key Stats

• Today's Range: $0.18 to $0.19
• 50-Day Range: $0.16 to $0.21
• 52-Week Range: $0.12 to $0.38
• Volume: 22,550 shs
• Average Volume: 93,283 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AVCNF Stock Analysis - Frequently Asked Questions

How have AVCNF shares performed this year?

Avicanna's stock was trading at $0.2029 at the beginning of 2025. Since then, AVCNF shares have decreased by 6.4% and is now trading at $0.19.
View the best growth stocks for 2025 here.

How do I buy shares of Avicanna?

Shares of AVCNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTC
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: OTC:AVCNF
• CIK: N/A
• Web: www.avicanna.com
• Phone: 1.647.243.5283
• Fax: N/A
• Employees: 87
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A